Pulmonary Hypertension (PH) is a complex and often misunderstood condition. Despite advancements in diagnostic tools and therapeutic options, it remains a significant cause of morbidity and mortality. This article aims to provide a comprehensive guide to help healthcare professionals better understand and manage PH.
PH is defined as a mean pulmonary arterial pressure ≥25 mmHg at rest, confirmed by right heart catheterization. It is classified into five groups based on etiology, clinical presentation, hemodynamic characteristics, and treatment strategy. This classification aids in the understanding of disease pathophysiology and guides therapeutic decision-making.
The pathophysiology of PH is multifactorial and involves vasoconstriction, vascular remodeling, and thrombosis in situ. The imbalance between vasoconstrictive and vasodilative substances, along with endothelial dysfunction, leads to increased pulmonary vascular resistance, resulting in right heart failure.
Diagnosis of PH is challenging due to the nonspecific nature of symptoms. A high index of suspicion is required for early detection. An echocardiogram is the initial screening tool, followed by right heart catheterization to confirm the diagnosis. Additional investigations like pulmonary function tests, CT scan, and V/Q scan may be needed based on the suspected etiology.
Management of PH is complex and requires a multidisciplinary approach. It includes general measures, targeted drug therapy, and surgical interventions. Early diagnosis and treatment can significantly improve the prognosis. Patient education and regular follow-up are vital elements of management.
PH is a challenging condition that requires a thorough understanding of its fundamentals for effective management. As healthcare professionals, it is our responsibility to stay abreast with the latest advancements in the field to provide optimal care to our patients. A comprehensive understanding of PH will undoubtedly contribute to better patient outcomes.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation